Nuvalent, Inc. (NUVL)

業務介紹

努瓦倫特公司(Nuvalent, Inc.)是一家處於臨床階段的生物製藥公司,為癌症患者開發療法。其主要產品候選藥物包括:

1. NVL-520 - 一種能夠穿透腦部的ROS1選擇性抑制劑,可抑制表達正常ROS1激酶域而不存在任何耐藥突變的ROS1融合蛋白,即使在存在使已批准和研究中的ROS1抑制劑產生耐藥的突變時仍保持活性,目前正處於I期臨床開發階段。

2. NVL-655 - 一種能夠穿透腦部的ALK選擇性抑制劑,旨在解決新興治療耐藥性、中樞神經系統相關不良事件以及可能限制第一、二、三代ALK抑制劑使用的腦轉移的臨床挑戰,目前正處於I/II期臨床試驗階段。

該公司成立於2017年,總部位於麻薩諸塞州劍橋。



Nuvalent, Inc., a clinical stage biopharmaceutical company, develops therapies for patients with cancer. Its lead product candidates are NVL-520, a brain-penetrant ROS1-selective inhibitor to inhibit ROS1 fusions that express the normal ROS1 kinase domain without any drug-resistant mutations and remain active in the presence of mutations conferring resistance to approved and investigational ROS1 inhibitors, which is under Phase I development; and NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, central nervous system-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under Phase I/II clinical trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.

公司網址

https://www.nuvalent.com